C

Cooper Companies

Global medical devices and vision care

Customer Success Specialist

Full-Time
$67k - $80k/yr
Senior
Bachelor's
Rockville, MD, USA
In Person

About the job

Requirements
  • At least 5 years of experience in fertility customer service, patient care, or clinical administration.
  • A proven track record of executing lead conversion to approval through diligent client management services.
  • A Bachelor's degree in Business Administration or Marketing.
  • High emotional intelligence to recognize signs of dissatisfied customers and deliver negative news sensitively.
  • Strong critical-thinking skills, business acumen, and ownership.
  • The ability to pressure-test established norms and legacy processes to improve productivity.
  • The ability to lead through influence, navigate ambiguity, and adapt to rapidly changing conditions.
  • Exceptional communication and interpersonal skills for building relationships with customers, partners, internal stakeholders, clients, nurses, and physicians.
  • The ability to obtain and manage medical records and documentation while protecting confidential donor and client information.
  • The ability to follow policies and procedures accurately and adhere to the Genetic Carrier Standard Operating Procedure.
Responsibilities
  • Qualify intended parents for premium plans.
  • Act as a liaison between the Refund Plans Team, Family Building Consultants, the Medical Review Team, partner clinics, and clients regarding eligibility and enrolled plans.
  • Communicate when additional service levels are needed and provide updates about plan status, expirations, withdrawals, and next steps.
  • Troubleshoot complex workflow processes and perform gap assessments in internal communications.
  • Prepare and participate in weekly medical reviews for applicants in premium plans, communicate with applicants several times per week, expedite reviews, and manage a large caseload.
  • Obtain medical records and documentation from clients and clinics and prepare charts for eligibility reviews.
  • Handle prospective and current client questions, address customer issues, and ensure timely short- and long-term resolutions.
  • Educate prospects and clients about Refund Plans, identify requirements and expectations, optimize conversions, and manage complex customer situations.
  • Partner with clients and clinics to increase speed to final match and identify poor-performing egg lots or high-euploid super donors.
  • Collaborate with DEB USA departments and initiate the Refund Plans withdrawal process.
  • Maintain electronic and paper client files, including entering and updating information.
  • Educate clients about genetic testing for selected donors who are identified as carriers.
Desired Qualifications
  • Previous in-vitro fertilization clinical experience.

About the company

Cooper Companies operates in two main areas: CooperVision and CooperSurgical. CooperVision makes a wide range of contact lenses to correct vision, supported by product development, manufacturing, and global distribution. CooperSurgical offers medical devices, fertility, and genomic products for women’s health, covering care from contraception through advanced reproductive treatments, with a vertically integrated model that controls research, development, manufacturing, and distribution. Compared with competitors, the company combines vision care and women’s health in one group and maintains end-to-end control of its product lifecycle, enabling integrated supply and service delivery to healthcare providers and patients worldwide. Its goal is to improve health outcomes for people through accessible contact lenses and comprehensive women’s health products and services, across the globe.

Company Size

201-500

Company Stage

IPO

Headquarters

San Ramon, California

Founded

1958

Get referred to Cooper Companies

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • September 23, 2026 Vision Centre unveiled six accelerated contact-lens launches over several years.
  • MiSight grew 20% organically and MyDay posted double-digit growth in Q3 2026.
  • Free cash flow hit $273 million quarterly, enabling $339.1 million buybacks.

What critics are saying

  • CooperVision destocking cut Q3 2026 revenue to $717 million and hits Q4.
  • July 31, 2026 accrued litigation liability reached $316.5 million from CooperSurgical’s 2023 recall.
  • Kirby McInerney’s September 2026 securities probe follows the 14.7% share drop.

What makes Cooper Companies unique

  • CooperVision combines R&D, clinical work, pilot manufacturing, and commercialization in Southampton.
  • CooperSurgical spans fertility, genomics, and women’s health across the reproductive-care journey.
  • CooperVision reaches more than 40 million people worldwide through contact-lens distribution.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Paid Vacation

Performance Bonus

Health Insurance

401(k) Retirement Plan

Life Insurance

Wellness Program

Professional Development Budget

Company News

Yahoo Finance
Sep 24th, 2026
CooperVision opens global innovation hub in Southampton, unveils six new contact lens products

The Cooper Companies has opened The Vision Centre, a global innovation hub in Southampton, England, to accelerate contact lens development for its CooperVision business. The facility integrates research and development, clinical expertise, pilot manufacturing and commercial capabilities under one roof. CooperVision announced six product advancements across myopia control, silicone hydrogel, toric and multifocal contact lenses, with launches planned over coming years. The pipeline includes a complete family of one-day contact lenses for myopia control and a premium one-day silicone hydrogel technology. Following the announcement, COO stock gained 1.4%. Year to date, shares have declined 31.6% against the industry's 2.8% growth. The company has a market capitalisation of $10.51 billion. CooperVision's products currently reach more than 40 million people worldwide.

Associated Press
Sep 24th, 2026
Cooper Companies shares drop 14.7% after missing Q3 revenue target by $30M

Cooper Companies' shares fell 14.7% on 10 September 2026 after the medical device company reported third-quarter revenue of $1.07 billion, missing analyst expectations of $1.10 billion by $30 million. The company attributed the shortfall to its CooperVision segment, which generated $717 million in quarterly revenue, flat year-over-year. Cooper Companies said it had "proactively reduced U.S. channel inventory" in CooperVision, which would continue to impact fourth-quarter results. The share price dropped from $63.48 to close at $54.17 following the announcement. Law firm Kirby McInerney has announced an investigation into possible securities law violations by the company and its senior management. No lawsuit has been filed yet.

Yahoo Finance
Sep 14th, 2026
Cooper Companies cuts 2026 forecast as contact lens demand weakens, CooperVision revenue drops to $717M

The Cooper Companies cut its fiscal 2026 profit and revenue forecasts after weaker-than-expected contact lens demand affected its CooperVision business. The company now expects adjusted earnings of $4.51–$4.55 per share, down from $4.58–$4.66, whilst revenue guidance was reduced to $4.23–$4.25 billion from $4.29–$4.32 billion. Third-quarter revenue came in at $1.07 billion, below Wall Street's $1.10 billion estimate. CooperVision revenue fell to $717 million, with management citing US channel inventory reductions that are expected to continue affecting the fourth quarter. The company completed its strategic review and decided to retain CooperSurgical rather than sell the business. Despite the challenges, Cooper increased its share-repurchase authorisation from $2 billion to $3 billion.

Yahoo Finance
Sep 10th, 2026
Cooper Companies Q3 earnings beat estimates at $1.15, revenues miss at $1.07B on US destocking

The Cooper Companies reported third-quarter fiscal 2026 adjusted earnings per share of $1.15, beating the Zacks Consensus Estimate of $1.11 by 3.6%. However, revenues of $1.066 billion missed estimates of $1.099 billion by 3.0%, impacted by US channel inventory reductions in its CooperVision segment. Shares fell 15.9% in after-hours trading following the announcement. The stock has declined 22.5% year-to-date, contrasting with the S&P 500's 11% gain. CooperVision revenues remained flat year over year at $717 million, pressured by inventory destocking. CooperSurgical grew 2% to $349.2 million. MiSight delivered 20% organic growth, whilst MyDay products recorded double-digit growth across multiple categories.

Yahoo Finance
Sep 9th, 2026
Cooper Companies reports $271.8M record quarterly free cash flow, retains CooperSurgical after strategic review

Cooper Companies reported third-quarter fiscal 2026 revenue of $1.066 billion, up about 1%, with non-GAAP earnings per share rising 4% to $1.15. The company generated record quarterly free cash flow of $273 million, bringing year-to-date free cash flow to $528 million, up 86% year over year. CooperVision revenue remained flat at $717 million due to planned US channel inventory reductions, though underlying consumer demand continued growing at mid-single digits. CooperSurgical posted 3% organic growth, with fertility revenue increasing 5% to $141 million. The board concluded its strategic review and decided to retain CooperSurgical, whilst authorising an additional $1 billion in share repurchases. For the fourth quarter, Cooper expects flat to 2% organic revenue growth and non-GAAP EPS of $1.05 to $1.09.